Quality of life measures
| 3 Months | 6 Months | 12 Months | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phenytoin | Valproate | Phenytoin | Valproate | Phenytoin | Valproate | ||||||||||||
| M | SD | M | SD | M | SD | M | SD | M | SD | M | SD | ||||||
| POMS Depression | 4.8 | 6.5 | 4.8 | 6.2 | 3.6 | 5.6 | 4.2 | 4.8 | 5.5 | 7.3 | 4.5 | 5.3 | |||||
| Tension | 5.7 | 5.9 | 7.6 | 5.9 | 3.4 | 3.6 | 8.0 | 6.1 | 4.6 | 4.7 | 6.9 | 5.4 | |||||
| Vigour | 11.3 | 4.8 | 10.6 | 4.0 | 13.3 | 3.8 | 10.0 | 4.7 | 12.1 | 4.0 | 10.2 | 4.4 | |||||
| Anxiety | 5.2 | 4.9 | 4.3 | 5.1 | 3.7 | 4.2 | 4.2 | 5.1 | 5.3 | 5.3 | 4.8 | 4.7 | |||||
| Fatigue | 5.6 | 5.7 | 5.4 | 5.0 | 3.2 | 2.6 | 5.9 | 4.9 | 4.5 | 4.1 | 5.6 | 5.0 | |||||
| Fatigue severity scale | 33.8 | 16.6 | 37.6 | 13.3 | 29.6 | 11.7 | 37.2 | 13.0 | 33.4 | 13.4 | 3.7 | 15.9 | |||||
| Physical complaints | 10.0 | 2.3 | 10.4 | 2.5 | 9.5 | 1.3 | 10.0 | 1.8 | 10.0 | 2.0 | 9.9 | 2.3 | |||||
| ADL dependency | 8.2 | 1.8 | 8.9 | 3.4 | 7.3 | 1.5 | 8.0 | 2.5 | 7.1 | 1.3 | 7.7 | 2.3 | |||||
| Cognitive complaints | 9.2 | 4.3 | 8.3 | 3.0 | 7.5 | 2.9 | 7.9 | 2.1 | 8.3 | 3.2 | 8.1 | 2.7 | |||||
| Impediment of daily functioning | 2.5 | 1.0 | 2.4 | 1.1 | 2.1 | 0.9 | 2.0 | 0.9 | 2.3 | 1.0 | 2.1 | 1.1 | |||||
| Satisfaction with health | 3.3 | 1.0 | 3.1 | 1.0 | 3.3 | 0.9 | 3.7 | 0.8 | 3.3 | 0.9 | 3.6 | 0.7 | |||||
| General wellbeing | 3.1 | 0.9 | 3.1 | 1.2 | 3.8 | 0.9 | 3.7 | 1.0 | 3.6 | 0.9 | 3.8 | 0.8 | |||||
The data are derived from 55 patients (27 with phenyroin, 28 with valproate) whose assessment was complete. ADL=Activities of daily living.